Option Care Health

Option Care Health

Option Care Health traces its roots to 1979, founded as Walgreens Infusion Services before spinning out and merging with BioScrip in 2019 under the leadership of John Rademacher. The merger created the nation's largest publicly traded, standalone infusion provider, combining Option Care's diversified payor relationships with BioScrip's chronic-condition specialty. The company operates without a controlling family or founder, governed by a public board after its 2015 separation from Walgreens Boots Alliance. Strategically, the firm deploys capital into three areas: home infusion pharmacy, alternate-site ambulatory infusion suites, and specialty pharmacy distribution. Its therapeutic mix covers immunology, directly treating conditions like Crohn's disease and rheumatoid arthritis with physician-prescribed Remicade and Entyvio infusions; anti-infective therapies for endocarditis and osteomyelitis; and parenteral nutrition for patients with gastrointestinal failure. The model targets the site-of-care shift from hospital outpatient departments — where a single infusion can cost three times the home-based rate — into the home and community settings. Confirmed relationships include contracts with UnitedHealth Group's Optum and CVS Health's Caremark for chronic immunoglobulin therapies. Operations extend across 50 states. In 2021, the company was briefly targeted for acquisition by Amedisys in a $3.6 billion deal before Amedisys itself entered a competing agreement. That transaction collapsed and Option Care instead accelerated organic growth, using balance-sheet capacity to repurchase shares and expand its ambulatory infusion suite footprint. CEO John Rademacher — previously president of the combined entity and an operating partner at Madison Dearborn — has prioritized nurse recruitment and EHR interoperability investment as scale levers. No adjacent philanthropic or family-office vehicles exist; the firm is a pure-play operating company with roughly 7,000 employees as of 2023. What differentiates Option Care Health structurally is its refusal to pursue hospital-system acquisitions or full-risk capitation. Instead, it remains a neutral downstream provider to multiple health systems and payors, positioning itself as the low-cost default when insurers mandate home-based care. This architecture avoids direct channel conflict with the hospital networks that also refer patients, while capturing the margin spread between hospital outpatient billing and home-infusion reimbursement.